Imaging study of using positron emission tomography for the effect of nootropics (tramadol) on the athletic performance

Imaging study of using positron emission tomography for the effect of nootropics (tramadol) on the athletic performance - PET imaging for the effect of tramadol

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009747

Enrollment

Registered

2013-02-01

Start date

2013-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy adults

Interventions

PET,MRI, blood concentration, urine concentration PET,MRI, blood concentration, urine concentration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects who have the ability to provide informed consent and adhere to the protocol.

Exclusion criteria

Exclusion criteria: Exclusion criteria: - with past or current history of psychiatric illness - with past or current history of serious medical illness and/or brain organic diseases - subject who is contraindicated for the use of MRI - with past or current history ofsevere liver disease, kidney disease, heart disease, allergy, or severe drug allergy - subject who are judged as not suitable for participation in this study

Design outcomes

Primary

Measure	Time frame
To investigate the effect of the nootropics on the serotonin transporter quantified by positron emission tomography	—

Secondary

Measure	Time frame
blod and/or urine concentration, MRI	—

Countries

Japan

Contacts

Public ContactAmane Tateno

Nippon Medical School Department of Neuropsychiatry

amtateno@nms.ac.jp+81-3-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026